VOR completes Phase III MG trial enrollment; global readout set for 2027
VOR says Phase III MG trial enrollment is completed. A key global readout is expected in 2027, alongside plans for an ocular MG study, with management citing China data on efficacy and durability.
The session highlighted completion of phase III MG trial enrollment, with a key readout expected in 2027, and plans for an ocular MG study. Robust efficacy and durability from China data are expected to translate globally, supported by a differentiated dual mechanism and strong commercial positioni…